Discovery

31. Gene Therapy for Inherited Retinal Diseases with Opus Genetics' Dr. George Magrath 7/1/2025

    In this episode of Cell & Gene: The Podcast, George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness.

32. Inside CRISPR-GPT With Yuanhao Qu 8/26/2025

    In this episode of Cell & Gene Podcast episode, Host Erin Harris talks to Stanford School of Medicine Ph.D. student, Yuanhao Qu, about his work developing CRISPR-GPT, an AI-driven multi-agent system designed to automate genetic experimental design and data analysis, making CRISPR experiments more efficient and accessible, even for non-experts.

33. Extracellular Vesicle Breakthroughs with Aegle Therapeutics' Dr. Gloria Matthews 6/17/2025

    In this episode of Cell & Gene: The Podcast, Host Erin Harris interviews Dr. Gloria Matthews, Chief Medical Officer of Aegle Therapeutics, a clinical-stage regenerative medicine company focused on developing therapies for rare and severe dermatologic and immunologic disorders.

34. Scaling CRISPR For Rare Disease With Aurora Therapeutics' Dr. Edward Kaye 3/10/2026

    On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases.

35. The Future of Rare Diseases with The Jackson Laboratory's Rare Disease Translational Center's Cat Lutz 2/27/2024

    Rare Disease Day is February 29, 2024, and in honor of this important day, Cell & Gene: The Podcast Host Erin Harris sits down with Jackson Laboratory’s (JAX) Rare Disease Translational Center (RDTC)'s VP, Cat Lutz.

36. The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D. 1/29/2025

    Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors.

37. CRI's Response to NIH Cuts with Alicia Zhou, Ph.D. 4/22/2025

    In this episode of the Cell & Gene podcast, Host Erin Harris speaks with Alicia Zhou, Ph.D., CEO of the Cancer Research Institute (CRI), about CRI’s mission to advance cancer immunotherapy and the critical role of federal funding, particularly from the NIH, in supporting basic and translational cancer research.

38. The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan 1/15/2025

    Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’ cell therapy products. They cover Artiva's "manufacturing first" approach to enabling scalable NK cell production, and much more.

39. Inside Sanofi's Genomic Medicine Vision with Mike Quigley, Ph.D. 9/24/2025

    On episode 112 of Cell & Gene: The Podcast, Michael Quigley, Ph.D., Chief Scientific Officer and Global Head of Research at Sanofi talks to Host Erin Harris about the establishment of Sanofi’s dedicated Genomic Medicine Unit (GMU). Dr. Quigley emphasizes in vivo delivery and process optimization to improve patient experience, scalability, and global access.

40. Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes 1/28/2026

    In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics' CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to move genetic medicine beyond rare disease into common cardiometabolic indications.